Surface modification of positively and negatively charged porous silicon nanoparticles and their biological applications by Uddin, Mezbah
  
 
 
SURFACE MODIFICATION OF POSITIVELY AND 
NEGATIVELY CHARGED POROUS SILICON 
NANOPARTICLES AND THEIR BIOLOGICAL 
APPLICATIONS 
 
     
Mezbah Uddin 
 
 
 
 
 
 
Master’s Thesis 
Department of Chemistry 
Medicinal Chemistry 
406/2012 
 
 
ii 
 
UNIVERSITY OF EASTERN FINLAND, School of Pharmacy 
Master Degree Program for Research Chemists 
MEZBAH UDDIN 
Master Thesis, 40 p 
Supervisors:  
Senior Scientist Docent Ale Närvänen and Researcher MSc. Jussi Rytkönen 
September 2012 
  
KEY WORDS: Nanotechnology, PEGylation, Opsonization, Zeta potential, Fluorescence intensity, 
Biofunctionalization. 
 
Porous silicon nanoparticles (PSiNPs) have drawn significant attention in recent years in the 
study of oncology due to their biocompatibility, favorable biodistribution, and efficient 
clearance or biodegradability. The clinical use of PSiNPs as nanocarriers in drug delivery 
depends on biologically nonspecific adsorption and immunological response. Minimization 
of the opsonization in the blood increases the half life of the particles and the capability to 
target tumors. In this project, the opsonization of PEGylated porous silicon nanoparticles was 
investigated as it is expected that PEGylation of TCPSi-NH2NPs with Me-PEG-COOH can 
contribute to minimization of the opsonization. PEGylated PSiNPs were also prepared using 
single step reaction between terminal amines in thermally carbonized porous silicon 
nanoparticles (TCPSi-NH2NPs) and carboxylic acid groups in mPEG-COOH by refluxing. 
PEGylated particles were characterized by measuring their size and zeta potential and the 
opsonized particles were analyzed by SDS-PAGE. The surface of TCPSi-NH2NPs was also 
conjugated with fluorescent molecule such as fluorescein-5-isothiocyanate (FITC) and by 
tailoring of the acid treated thermally hydrocarbonized porous silicon (UnTHCPSi) NPs by 
associating with fluoresceinamine isomer-1 (FluorA) activated with DIC/NHS activator. 
FITC labeling TCPSi-NH2NPs were further modified by conjugating stearylated NickFect 51 
(NF51) cell penetrating peptides (CPPs) and radioactive iodine labeled stearylated NickFect 
cell penetrating peptides. Fluorescent labeled NPs were characterized with zeta sizer and 
fluorescence spectroscopy. The surface modified PSiNPs can be loaded with targeted 
therapeutic compounds and studied their biodistribution both in vivo and in vitro. 
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1. Introduction 
1.1. Nanotechnology 
 
Biomedical process has been remarkably impacted over the preceding decades due to 
evolution of micro and nanotechnology. Quantum dots, controlled released nanoparticles, 
targeted delivery and cancer nanotechnology are ideal examples. Practical employment of 
many applications is still difficult but high rate of evolution is raising hope, for innovative 
biomedical process in near future. [1] 
Nanotechnology is an interdisciplinary study area comprising physics, chemistry, biology, 
engineering and precise diagnosis. Treatment of different diseases especially cancer can 
adopt with it [2, 3]. Size of nanoparticle is usually 1 nanometer to few hundreds nm which 
fits well with the size of biological molecules such as antibodies. Nanoparticles can also have 
very good interactions both on surface and interior cells of biomolecules which is very 
effective for syndrome diagnosis and treatment used in nanomedicine.  
Nanodevices such as nanochips, nanosensorss etc. are evident for in vitro and ex vivo 
purposes [4, 5]. Biocompatibility, in vivo kinetics, capability to break out the 
reticuloendothelial system (RES), targeting efficiency, severe, persistent toxicity and cost, 
effectiveness are main challenges in preclinical animal models and clinical translation of 
nanotechnology for in vivo purposes. Nanoparticles can specially work in oncology where 
the absorbent tumor vasculature can let for superior tissue permeation than normal organs. 
Nanoparticles can help to carry diagnostic or therapeutic agents to enter in cells, intervening 
molecular interactions and to identify molecular changes in a susceptible approach.   
Nanotechnology made a great progress in biological imaging and drug delivery. They are 
now employed as fluorescent probes, drug carriers and contrasts agents in therapeutic and 
diagnostic sectors [6-10]. Gold nanoparticles, silver nanoparticles, silicon nanoparticles and 
many more are used in nanomedicine. We are interested to monitor biological characteristics 
of porous silicon nanoparticles. 
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1.2. Porous Silicon (PSi) 
 
Porous silicon has holes in its nanostructure with a large surface to volume ratio (500 -
m
2
/cm
3
). Porous silicon was first prepared in 1956 by Arthur Uhlir Jr. at the Bell Labs in the 
V.S. Porous silicon has many applications in drug delivery, biological imaging, photonics, 
chemical sensing and so on. 
 
1.2.1. Properties of Porous Silicon 
1.2.2. Structural Properties of Porous Silicon and Their Effect  
 
Basic structural parameters are pore size, porosity and porous thickness. Field emission 
scanning electron microscopy (FESEM), transmission electron microscopy (TEM), atomic 
force microscopy (AFM) or scanning force microscopy (SFM) etc are usually used to study 
structure of porous silicon. Porous silicon can be bio-inert, bioactive and resorbable 
depending on porosity [11]. In in-vitro study, porous silicon samples were exposed to 
simulate body fluid containing similar ion concentration as in human blood. They were 
investigated for longer time. High porosity mesoporous layers were completely removed 
within a day but low or medium porosity micro-porous layer were stable with hydroxyapatite 
growth. 
 
1.2.3. Chemical Properties of the Porous Silicon 
 
Porous silicon has high surface area with high density of Si dangling bonds and adulterations 
like hydrogen and fluorine. Adulterations are usually formed during PSi formation from 
electrolytes. Initially porous layer surface is covered by SiHx (x= 1, 2, 3) bond. It fades 
during annealing (300-500
0
C). PSi surface oxidizes gradually in atmosphere and finally 
whole surface is oxidized. Light and elevated temperature increases oxidation. A blue shift in 
luminescence spectra is observed after oxidation [12] and electrical conductivity and optical 
properties are also influenced. Level of impurity of fluorine depends on type of electrolyte 
and identified in freshly prepared porous silicon. Fluorine exists as SiFx (x= 1, 2, 3) and it is 
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replaced by SiOH during reactions with water vapour of atmosphere. So usually fluoride 
concentration decreases with time. 
 
1. 3. Surface Functionalization of Porous Silicon 
 
PSi is not good for commercial purposes because it is unstable with meta-stable Si-Hx 
termination. Meta-stable hydro-silicon can oxidize and degrades surface structure. So 
passivation of PSi surface is important to have good electrical contacts on PSi. 
 
 
1.4. Advantages of Porous Silicon 
 
Porous silicon micro-particles are very useful for controlled drug delivery because they are 
less toxic. They are good for chronic use as they disintegrate in body whereas carbon 
nanotubes degrade. Secondly, desired surface area, free volume and pore size (few 
nanometers to several hundreds of nanometers) can be achieved by electrochemical 
fabrication. Thirdly the surface of porous silicon is tailored with wide variety of organic or 
biological molecules (drugs, peptides, antibodies, proteins etc). 
Fourthly, porous silicon offers excellent optical properties because it exhibits fluorescence 
deriving from silicon quantum dot structures [14]. It is useful for diagnostic or therapeutic 
purposes. Additionally, porous silicon is simple enough to replace more complicated clinical 
devices [15-17]. 
 
 
1.5. Porous Silicon Nanoparticles  
 
Porous silicon nanoparticle is commonly used as nanomedicine. They have excellent 
properties like biocompatibility, favorable bio-distribution, biodegradability for controlled 
drug delivery. Nanoparticles have large pay loads, stability avidity and enhancement. They 
can be used in multiple purposes because of their unique size and on elevated ratio of surface 
to volume, tunable optical, electric, magnetic and biological features. They can have various 
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sizes and shapes, chemical constituents, surface chemical features and hollow or solid 
structures. So they are suitable for drug delivery vehicles, distinction agents and diagnostic 
devices. NPs are smaller than cells and can effect in vivo applications. For example, in cancer 
tissue, NPs  can remain in the area even after extravasating from leaky tumor and shows 
enhanced permeability and retention effect [18] for signaling or therapy [19].  
Moreover, SiNPs are commercially available and easily separable from aqueous suspension. 
Large specific surface of most SiNPs can be easily functionalized and delivered into living 
cell. 
 
1.5.1. Amino-derivatized Thermally Carbonized Porous Silicon 
Nanoparticles (TCPSi-NH2 NPs) 
 
The most important characteristics of TCPSi-NH2-NPs are summarized in following table  
Table 1.1 
 
Table 1.1: Features of the plain TCPSi-NH2
 
NPs 
Sample Surface Area 
(m
2
/g) 
Pore Volume 
(cm
3
/g) 
Pore Size (nm) Particle Size 
Distributions 
(nm) 
TCPSi-
NH2 
97.0372 0.508017  9.26 170 
 
 
 
 
Figure 1.1: Chemical structure of the TCPSi-NH2 
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TCPSi-NH2-NPs contain both primary and secondary amine (figure 1.1). Primary amine is 
more reactive than secondary amine. Surface of TCPSi-NH2NPs can be modified when 
primary amine forms amide bond with succinimidyl ester terminated surface layer is formed 
during reaction between carboxyl acid (-COOH) and N-hydroxysuccinimide. Surface of 
TCPSi-NH2NPs can also be modified by covalently attaching amine specific –N=C=S group 
to primary amine.   
 
                                             
1.5.2. Carboxyl Acid-derivatized Thermally Hydrocarbonized Porous 
Silicon Nanoparticles (UnTHCPSiNPs) 
 
Our investigated UnTHCPSiNPs had pore size ~10 nm with 135-140 nm particle size 
distribution. They contain carboxyl group (-COOH) (figure 1.2) which can react with NHS in 
presence of di-isopropyl carbodimide (DIC) to form succinimidylester (- COOSuc) surface. 
This terminated surface further reacts with primary amine to form amide bond. 
 
 
Figure 1.2: Chemical structure of the UnTHCPSi. 
 
 
 
1.6. Polyethylene Glycol (PEG) Molecule  
 
PEG has repeating ethylene ether units and very attractive for conjugation. It is most 
frequently used in biomedical applications due to high solubility in water. PEG is very 
flexible and can be cleared from body. 
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1.7. Fluorescent Molecules and Their Applications  
 
Derivatized fluoresceins, such as fluoresceinamine isomer-1(FluorA) or fluorescein 
isothiocyanate (FITC), are often utilized in many biological purposes. These derivatives 
contain a reactive substituent on the phenyl ring for coupling reactions.  
                                         
Figure 1.3: Stucture of fluorescein isothiocyanate (FITC) and fluoresceinaminismer-1(FluorA). 
FITC is the isothiocyanate (-N=C=S) derivative of the original fluorescein molecule and (-
N=C=S) is a reactive group, replacing a hydrogen atom on the bottom ring of the structure. 
This derivative can easily react with nucleophiles including amine and sulfhydryl groups. 
FluorA is the amine derivative of the original fluorescein molecule which reacts with 
carboxyl acid ester groups to form amide bond. Their excitation and emission spectrum peak 
wavelengths are approximately 495 nm/521 nm. Like most fluorochromes, it has a tendency 
to photobleaching. This feature is challenging, so it has to be overcome for the biological 
applications where greater photostability, higher fluorescence intensity, or different 
attachment groups are needed. 
Biomolecules, cells, tissue sections [20] and fluorescent molecular probes are widely used for 
labeling. These probes are used in vivo purposes for example to image target tissue in live 
animals or as blood pool contrast in human subject. Green emitting fluorescein dyes are used 
for retinal angiography in human subject [21]. Cerebral vertebral arteries can be visualized 
with near infra red (NIR) emitting indocyanine green [22, 23]. Labeled fluorescent dyes, 
fluorescent micro-particles and nanoparticles are used in many imaging techniques. 
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1.7.1. Fluorescence Detection 
 
Fluorescence detection is useful for biological assays [24, 25] but higher sensitivity is 
required to identify low concentrated objective molecule [26-29]. There are many methods 
for detection [30, 31] like surface enhanced fluorescence (SEF) on metal nanostructures [32]. 
When a fluorophore is confined near to surface of metallic nanoparticles [33, 34] 
fluorescence enhances. Conjugation of fluorophore with radiating Plasmon from metallic 
particles causes SEF. When fluorophore is near to metal core then fluorescence quenched 
completely. Highest enrichment occurs when fluorophore is 10 nm from metal surface [48]. 
Small particles quench fluorescence due to absorption and big particles increases 
fluorescence due to dispersion [35]. 
 
 
1.8. Cell-penetrating Peptides (CPPs)  
 
CPP carries cargo into cells usually via endocytosis to the endosomes of living mammalian 
cells. Cargoes are from small chemical molecules to nanosize particles and large fragments of 
DNA. Cargo conjugates with CPPs either through chemical linkage via covalent bonds or 
through non-covalent interactions. 
CPPs have great potential as in vitro and in vivo delivery vectors. CPPs pose an amino acid 
composition of high relative abundance of positively charged amino acids or non polar 
hydrophobic amino acids. Initially it was found that trans-activating transcriptional activator 
(TAT) from Human Immunodeficiency virus 1 (HIV-1) internalized from surrounding media 
by numerous cell types in culture [36]. Many CPPs have been identified and small synthetic 
analogues with more effective protein transduction properties have been established [37]. 
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Figure 1.4: Minimizing proteolysis effects for CPP. (http://en.wikipedia.org/wiki: Mechanism_ cell _uptake_ 
for_CPP.jpg, 26 April 2009.) 
 
Extracellular materials are gene or nanoscale synthetic delivery system. They can not 
transport through plasma membrane of a cell. Various cell penetrating peptides (CPPs) can 
overcome this problem through receptor independent pathway. CPP mediated NPs can be 
internalized by a cell and have high potential for delivering imaging and therapeutic agents 
into the cells. 
 
 
1.9. Opsonization 
 
A process in which pathogens are layered and neutralized by immune system is called 
opsonization. An opsonized pathogen is killed either by uptaking or direct neutralization. 
RES is an immune system where circulating and macrophages, liver kupffer cells and spleen 
and other lymphatic vessels neutralize foreign material like bacteria or viruses [38]. Opsonin 
protein conjugate with foreign bodies and coat it`s surface (figure 1.5 A, B) [39, 40]. 
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Figure 1.5(A): Polyethylene glycol reduces reticuloendothelial system uptake (A1), opsonized NPs (A2), 
opsonized NPs conjugated with macrophages (A3) and   transported to the liver (A4). (Jokerst JV, Lobovkina T, 
Zare RN, Gambhir SS: Nanoparticle PEGylation for imaging and therapy. Nanomedioine, 2011, 6 (4), 715–
728.) 
 
Phagocytic cell uptake the material and deliver it to the liver or spleen for degradation 
(Figure 1.5 A3–A4). Extra phagocytic macrophages are eternally sited in the liver. For 
example, Kupffer cells serve as major filter for many types of NPs with major interference 
(long t1/2) [41]. 
 
 
 
Figure 1.5(B): (B) PEGylated NPs (B1) minimize opsonization (B2) and reduction of NP accumulation in liver 
(B3). (Jokerst JV, Lobovkina T, Zare RN, Gambhir SS: Nanoparticle PEGylation for imaging and therapy. 
Nanomedioine, 2011, 6 (4), 715–728.) 
 
PEG polymer on a NP surface minimize opsonization (Figure 1.5B2) and increases t1/2. It 
protects recognition by monocytes and macrophages and thus NPs circulates [39, 40]. 
Hydrophilic PEG can reduce hydrophobic particles. Aggregation causes poor t1/2. Initially, 
NPs aggregate because attraction between particles is stronger than solvent [40, 42]. 
According to Derjaguin-landau-Verwey-Overbeek (DLVO) theory, NPs aggregates due to 
their high surface energy [43, 44]. Electrostatic repulsive potential [44] and Vander Walls 
attraction potential is important factor for aggregation of spherical NPs. PEG reduces surface 
energy of NPs and Vander Waals attraction [45-47]. 
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1.10. Role of Zeta Potential in Characterization of Nanoparticles 
 
 
 
Figure 1.6: Schematic representation of the zeta potential. (http://www.horiba.com/scientific /products /particle-
characterization/technology/zeta-potential/)  
 
 
Zeta potential is the electric potential at the slip plane between the bound layer of diluents 
molecules surrounding the particle and bulk solution. It depends on particles surface charge 
and diluents solution. Higher zeta potential means greater electrostatic repulsion between 
particles and less aggregation. 
Zeta potential is used to characterize nanoparticles. Size, zeta potential and size distribution 
can be measured with dynamic light scattering. Zeta potential determines stability of colloidal 
system and particle –particle interactions within suspension. 
Minimum value of zeta potential to prevent aggregation depends on particular sample but 
usually it is between -30 mV to +30 mV. To reduce aggregation of a sample for drug delivery 
and pharmaceutical applications higher zeta potential is required. For removing too small 
particles in water treatment applications, low zeta potential is necessary. 
According to Derjaguin Landau Verwey Overbeek (DLVO) theory, dispersion stability 
depends on attractive Vander Waals and repulsive electrostatic forces. If repulsive 
electrostatic force overcomes attractive vdw force, nanoparticles will be stable and free of 
aggregation. So nanoparticles with adequate density of surface charge will not aggregate. By 
screening charges with counter ions can favor vdw forces which are crucial for surface 
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functionalization such as biocompatibility of fluorescent nanoparticles, nanoparticle 
clustering, non specific adsorption of proteins (p), release cytotoxic ions (CT). 
Biofunctionalization can cause surface charge neutralization which decreases dispersion.  
Zeta potential can identify interaction between active substance and carrier. It ensures 
whether drug encapsulated in body or adsorbed on surface. Adsorbed drug can not be 
protected from enzymatic degradation or released fast after degradation. 
 
 
1.11. Surface Modification 
 
NPs have some shortcomings for clinical use. They can be uptaken by reticuloendothelial 
system (RES) and thus they are quickly shuttled out of circulation to liver, spleen or bone 
marrow. Another disadvantage is binding of NPs to non-targeted spots. Due to RES 
accumulation, NPs become toxic. NPs have tendency to aggregate and can cause entrapment 
in liver, lungs or elsewhere due to capillary occlusion [48]. So surface modification of NPs is 
necessary to overcome these problems and it can be done with PEGylation. 
Fluorescence molecular probes are limited for real time imaging studies due to several 
limitations such as short stokes shift, poor photochemical stability, sensitivity  to buffer 
composition, photo-bleaching and decomposition , non-targeted accumulation and faster rate 
of photo-bleaching , still they are used due to low cost, commercial availability and ease of 
use. Organic dyes such as fluorescein [49, 50], rhodamin [51, 52], cyanine [50, 53], alexa 
dyes [50, 54], oxazines [55, 56], porphyrin [57], phthalocyanins [58] show better chemical 
and optical properties. Usually organic fluorophores are used as luminescent bio-pointer but 
they have some limitations. Reliable determination of cancer biopointers needs extremely 
sensitive and photo-stable probes with sophisticated fluorescent imaging detection system. 
Optical based in vivo imaging is more challenging than X-ray computed tomography (X-ray 
CT) or magnetic resonance imaging (MRI) due to many reasons such as sharp absorption of 
optical signal by body tissue and fluid in UV and visible range, weak tissue penetration 
depth, light dispersion by tissues, weak spatial image resolution. 
Optimized particle sized of nanoscales materials is necessary because they are easily 
consumed by cells. Quantum dots and dye loaded nanoparticles are commonly used for real 
time imaging of cells. QDs exhibit less photo-bleaching. Most of them are cadmium based 
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and have cytotoxicity due to heavy metal ions [59, 60]. They have less quantum yield than 
organic dyes. QDs are hydrophobic and cause poor solubility into biological buffers and 
quenching in aqueous environment. Under intense excitation of light, they exhibit irreversible 
photo-degradation. So fluorescence molecule needs to be functionalized. Our aim is to use 
fluorescence molecule with porous silicon nanoparticles to overcome those limitations. 
Covalent and non-covalent bonding processes are two usual chemical approaches for 
conjugating molecules into silicon naoparticles. Dye can be covalently bonded with silicon 
nanoparticles, or entrapped into silicon naoparticles by electrostatic interactions. Covalently 
bound PEG chains are more effective because they have longer blood circulation half lives. 
Covalently bound fluorescent molecule can reduce dye leakage. 
 
 
1.12. PEGylation  
 
Covalently grafting, entrapping or adsorbing a particle surface with polyethylene glycol 
(PEG) chains is PEGylation. It minimizes opsonization which affects system uptake and 
pharmacokinetics. It reduces rate of mononuclear phagocyte system uptake and increases 
circulation half life of porous silicon nanoparticles and encapsulated drugs. Cellular 
interactions and bio-barrier transport may prove superior with targeting ligands like 
antibodies. Antibodies favor uptake by macrophages of reticuloendothelial system (RES). 
PEG chains can conjugate with biodegradable nanoparticles as copolymer. Numbers of PEG 
chains are constantly available. PEG chains can attach to NP surface or other candidate 
molecule and reduce some challenges (fig 1.7). 
 
Figure 1.7: PEGylated NP, containing yellow colored metallic or polymeric core with red colored cloud of PEG 
chain. (Jokerst JV, Lobovkina T, Zare RN, Gambhir SS: Nanoparticle PEGylation for imaging and therapy. 
Nanomedioine, 2011, 6 (4), 715–728.) 
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PEGylated nanoparticles reduce RES uptake and increases circulation time than uncoated 
NPs [40]. It is helpful in drug delivery and imaging purposes.  
Coagulation decreases due to passivity of surfaces and non-targeted conjugation is also 
reduced. Charged based contact of proteins and small molecule are diminished. Solubility 
increases in buffer and serum due to hydrophilic ethylene glycol. EPR effect changes due to 
PEGylated NPs [61, 62]. For these reasons, PEGylated nanoparticles store very less in liver 
than non-PEGylated NPs and they are also exhibit higher tumor accumulation [63]. 
  
 
1.12.1.  Affecting Factors on PEGylation  
 
 
Figure 1.8: Polymerization of ethylene glycol to form PEG which contains linkage group (R1) and terminus 
group (R2). (Jokerst JV, Lobovkina T, Zare RN, Gambhir SS: Nanoparticle PEGylation for imaging and 
therapy. Nanomedioine, 2011, 6 (4), 715–728.) 
 
 
Most PEG molecules have two ends. One end (R1) attaches to NP surface and other end (R2) 
interact with solvent. Longer PEG is represented by m-PEG and PEG is often illustrated as 
polyethylene oxide. The behavior of PEG-NP construct is affected with increased t1/2. 
 
 
1.12.2. Different Sized NP  
 
t1/2 depends on type of NP to be PEGylated like their size , charge and composition. For liver 
accumulation, ganglioside liposomes are size dependent but phosphatidylserine liposomes are 
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size independent. Positively charged NPs with size more than 100 nm can be rapidly cleared 
from circulation [64, 65]. NP composition is also very important for PEGylation. 
 
 
1.12.3. Length & Conformation of PEG Chain  
 
Grafted PEG layer on NP surface and polymer conformation are related. 
F= αn3/5  
Here, F represents Flory radius. Polymer conformation can be described on basis of Flory 
radius. n represents the number of monomer per polymer chain and length of one monomer in 
Angstrom is α [66, 67]. 
 
 
Figure 1.9: Flory radius VS no of monomers (n) for PEG. (Jokerst JV, Lobovkina T, Zare RN, Gambhir SS: 
Nanoparticle PEGylation for imaging and therapy. Nanomedioine, 2011, 6 (4), 715–728.) 
 
PEG chains can have two main conformations on basis of surface coverage. 
 
 
Figure 1.10: Gold nanoparticles with PEG on surface. (A) Contains mushroom configuration and (B) contains 
brush configuration.   (Jokerst JV, Lobovkina T, Zare RN, Gambhir SS: Nanoparticle PEGylation for imaging 
and therapy. Nanomedioine, 2011, 6 (4), 715–728.) 
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PEG chains with lower surface density are called mushroom conformation where distance 
between attachment points of polymer is larger than F (Figure 1.10A). In mushroom 
conformation polymer chain have roughly sphere with Flory radius. Polymer with bigger 
graft density D<F) is called brush room configuration. In brush configuration, long thin 
bristles of PEG enlarge from NP surface (figure 1.10B) [66, 67]. Number of repeating units 
necessary to transform from mushroom to brush arrangement depends on types of PEG and 
NP. When distance of PEG molecules on surface close to F then mushroom conformation 
coverts to brush conformation. NPs containing brush PEG have denser coating and they 
shield NPs from RES better. Usually brush PEG conformation has longer circulation time. 
Typically, larger PEG is used for smaller therapeutic materials. It avoids excretion by kidneys 
and maintains high concentration for longer time by increasing recirculation. So oligos and 
small molecules are coated with PEG 20,000-50,000 Da. It increases hydrodynamic radius 
and reduces t1/2. So larger NP ranges from 50-100 nm are usually coated with smaller PEG 
(3400-10,000 Da). Kidney excretion of non-conjugated PEG reduces with bigger molecular 
weight but liver uptake increases. For example, liposome circulation with PEG 5000 is very 
long (7 h) than PEG 2000 or PEG 750 (~1h). Longer molecular weight PEG has longer t1/2 on 
QD [70-72]. In mushroom configuration, If PEG is larger then less copy number can be 
loaded on a NP.  
 
1.12.4. Terminal Portion 
 
In vivo behavior is influenced by terminal end of PEG. Methoxy or alcohol terminal groups 
diminish non specific binding of lysosyme and fibrinogen [73, 74]. mPEG is usually very 
ubiquitous. NPs with negative charge (thiol or carboxy) makes surface of cell negatively 
charged and causes fewer phagocytic events. Simple hydroxyl group can diminish non 
specific binding [75].  Succinimide, maleimide or alkyne reactive group assists binding of 
secondary targeting ligand [76] but it is challenging due to steric hindrance. 
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1.13. Biofunctionalization  
 
NPs conjugate with biomolecules as address tags. They conduct NPs to exact sites of body, 
exact organelles in body or transform protein or RNA in living cells. Monoclonal antibodies, 
aptamers, streptavidin or peptides are common address tags. They are covalently coupled and 
should be in controlled number per nanoparticles. 
For successful biofunctionalization reactions [77], few requirements are very important. 
Activity of biomolecules must be removed. Signal of nanoparticles should not be slowed 
down. Linkage sites of NP surface should be covered and stability of biomolecule-
nanoparticle coupling should be controlled. Finally, width of nanoparticle shell should stay as 
tiny as nanoparticles. 
 
 
Figure 1.11: Different approach of association of biomolecules to nanoparticles comprise direct physisorption 
(A) facilated physisorption (B) chemically connected biomolecules with cross-linkers adsorbed on NP (C) direct 
chemical coupling with NPs (D) biotin-streptavidin targeted coupling of biotinylated biomolecules. (M. Murcia 
& C. Naumann: Biofunctionalization of Fluorescent Nanoparticles. (Nanotechnologies for the Life Sciences 
Vol.1.Edited by Challa S. S. R. Kumar, Copyright 8 2005 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim, ISBN: 3-527-31381-8. 
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There are several strategies to bioconjugate nanoparticles. Simple adsorption of biomolecules 
to nanoparticle surface is least demanding (figure 1.11A). Activity of adsorbed biomolecules 
change and it is difficult to control amount of adsorbed biomolecules per nanoparticle. 
Physisorption or noncovalent coupling of biomolecules to other biomolecules is another 
technique (figure 1.11B). Here biomolecules are connected in appropriate direction. Reactive 
groups of biomolecules can also conjugate with cross-linker molecules by physisorption or 
chemisorptions (figure 1.11C). Chemical conjugation is possible for coupling of 
oligonucleotides to nanoparticles through mercapto groups (figure 1.11D) [78-80]. To control 
number of biomolecules per nanoparticle, a separation step is needed [81]. Usually it is done 
by gel electrophoresis. Linkage of biotinylated ligands or target biomolecules to streptavidin 
or avidin-tailored nanoparticles is very specific (figure 1.11E) [82, 83]. Biotin binding 
proteins, avidin or streptavidin is used as linker molecules. 
 
 
1.14. General Conjugation Reactions 
 
Nanoparticles are conjugated with covalent coupling. One popular coupling process is 
reaction between primary amine and carboxylic acid group.  
 
 
 
Initially a carboxylic acid reacts with 1-ethyl-3-(3 dimethylaminopropyl)carbodiimide 
(EDAC) and N-hydroxysuccinimide (NHS) to form an acyl amino ester. Then this ester 
reacts with primary amine to form a stable amide bond. 
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Another approach is reaction between thiol and maleimide groups. At certain pH, a good 
yield of stable thioester bond is formed. It directly connects maleimide functional ligands to 
thio groups of proteins. Thiols can be prepared with heterobio-functional crosslinkers with 
one thiol end group or by reducing disulfide bonds within the target protein. 
 
 
 
Coupling of two thiols to form a disulfide linkage is another approach. Disulfide bond is 
usually labile in biological fluids. 
 
 
Covalent linkage between aldehyde and amine groups form hydrazide bond. Mild oxidation 
of carbohydrate forms reactive aldehyde group. 
  
 
 
Chemical reaction between two primary amines is applied for bioconjugation. 
Homobiofunctional crosslinkers like glutaraldehyde can precede coupling reaction [84, 85]. 
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In this study, one of our goal was to ensure efficient surface modification of the positively 
charged amino modified thermally carbonized porous silicon nanoparticles (TCPSi-NH2NPs) 
which has primary amine on the surface through PEGylation so that resulting particles can 
minimize the opsonization which involved in mononuclear phagocytic uptake of 
nanoparticles for optical data storage and other technical applications in related fields. Our 
another goal was surface functionalization of negatively charged acid treated thermally 
hydrocarbonized porous silicon nanoparticles (UnTHCPSiNPs) having carboxyl acid group 
on the surface with fluoresceinamine isomer-1(FluorA) and TCPSi-NH2NPs with 
Fluorescein-5-isothiocyanate (FITC) so that producing fluorescent labeling particles can 
optimize photostability, sensitivity and photbleaching and eventually they can act as an 
effective bioimaging probe. Subsequently stearylated NickFect 51 (NF51) CPPs was 
introduced to the FITC labeled TCPSi-NH2NPs and conjugating radioactive iodine labeled 
stearylated NickFect CPPs to check the CPPs conjugation. 
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2. Experimental 
 
2.1. Materials 
 
Undecylenic acid modified thermally hydrocarbonized porous silicon (UnTHCPSi) 
nanoparticles (NPs) were prepared by Docent Jarno Salonen department of Physics and 
Astronomy University of Turku. Amino-modified thermally carbonized porous silicon 
(TCPSi-NH2) nanoparticles (NPs) were fabricated by Wujung Ju, Department of applied 
Physics at the University of Eastern Finland. Alpha-methoxy-omega-carboxylic acid 
poly(ethylene glycol) (MeO-PEG-COOH) (Iris Biotech -GmbH), N,N-
Diisopropylcarbodiimide (DIC) (perceptive Biosystems GmbH), N-Hydroxy-succinimide 
(NHS) (Fluka), O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU) (GL BioCHEM LTD), N,N-Diisopropylethylamine (DIPEA) (Fluka), Fluorescein-5-
isothiocyanate (FITC), Fluoresceinamine isomer-1(FluorA) and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were purchased from SIGMA ALDRICH, Cell 
penetrating peptide (CPP) was provided by University of Tartu; cell culture medium (FCS, 
PSG). Phosphate Buffer Saline (PBS), Dimethylformamide (DMF), Human EDTA Plasma. 
Ethanol (EtOH). 
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2.2. Surface Functionalization of TCPSi-NH2 with MeO-PEG-COOH 
(PEGylation) 
2.2.1. Preparation of PEGylated TCPSi-NH2NPs by Using DIC and 
NHS as an Activator Reagent 
 
To optimize the activation concentrations of DIC and NHS the carboxyl group 780µL  of 
5.768 kDa MeO-PEG-COOH (10 mg/mL in DMF) was activated separately by adding 6.25, 
12.5, 18.75, 25, 50, 75, 100, 125, 150µL of DIC(100 mg/mL in DMF) and 5.75, 11.5, 17.25,  
23, 46, 69, 92, 115, and 138 µL of NHS (100 mg/mL in DMF) at room temperature to 
prepare an active succinimidyl ester-terminated intermediate. After activation 0.2 mg 
(105.26µL) of amino-modified TCPSiNPs (1.9 mg/mL in DMF) was added into the reaction 
system to produce the PEGylated TCPSi NPs. Paparticles were mixed by using end over end 
mixer (BIOSAN Bio Rotator RS-Multi) overnight at room temperature to complete the 
reaction and resulting PEGylated TCPSiNPs were washed by six cycles of centrifugation 
(Eppendorf centrifuge 5415D, 13200 rpm for 20 min) and washing (three times with DMF 
and three times with water) to remove unreacted MeO-PEG-COOH, DIC and NHS.   
 
2.2.2. Preparation of PEGylated TCPSiNH2NPs by Using HBTU and 
DIPEA as an Activator Reagent 
 
In order to optimize the activation concentrations of HBTU and DIPEA for the preparation of 
PEGylated TCPSiNPs, the carboxyl group of 390 µL of 5.768 kDa MeO-PEG-COOH (10 
mg/mL in DMF) was activated separately by adding 37.9, 75.8, 151.6, 303.2, 454.8, 606.4, 
758 µL of HBTU (100 mg/mL in DMF) and 12.9, 25.8, 51.6 103.2, 154.8, 258 µLof DIPEA 
(100 mg/mL in DMF) at room temperature. After activation 0.1mg of amino-modified 
TCPSiNPs (1.9 mg/mL in DMF) were added to produce PEGylated TCPSiNPs. Particles 
were washed as described above. 
2.2.3. Preparation of PEGylated TCPSi-NH2NPs by Refluxing of 
Amino-modified TCPSi-NH2NPs and MeO-PEG-COOH  
 
In the third method of PEGylation, 0.3 mg of TCPSi-NH2NPs and 1170 µL of MeO-PEG-
COOH (10 mg/mL) were taken into 10 mL round bottom flask refluxed overnight stirring 
with a magnetic stirrer and finally cooled at room temperature. The unreacted Me-PEG-
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COOH was removed by washing three times with 1mL of DMF and then three times with 
1mL of water as described above. After each centrifugation an ultrasonic bath was used to re-
suspend the PEGylated-TCPSiNPs in solution. 
 
2.2.4. PEGylation of TCPSi-NH2 with MeO-PEG-COOH of Different 
Size (5.768kDa, 11kDa and 25kDa) 
 
 780 µL of 5.768, 11, and 25 kDa of MeO-PEG-COOH (10 mg/mL in ethanol) were taken 
into three separate Eppendorf tubes and 50 µL of DIC (100 mg/mL in ethanol) and 46 µL of 
NHS (100 mg/mL in EtOH) were added followed by 0.2 mg (105.26 µL) of TCPSi-NH2NPs 
(1.9 mg/mL in EtOH) into each tube. Particles were mixed using end over end mixer 
overnight at room temperature to complete the reaction. Centrifugation was performed to 
remove the supernatant and particles were washed three times with 1mL of EtOH and finally 
washed three times with 1mL of water as described above.  After washing 50 µg of sample 
was taken from each tube and diluted with water to 3 mL for size and zeta potential 
measurement. 
 
2.2.5. Opsonization 
 
150 µg of PEGylated TCPSi-NH2 nanoparticles were suspended into 200 µL of a solution 
containing 1:1 ratio of PBS (pH = 7.4) and human plasma (HP). Particles were incubated for 
15 minutes at 37
o
C in Termaks incubator, centrifuged for 10 minutes and washed three times 
with 1mL of water as above. Finally 50 µg PEGylated TCPSi-NH2 nanoparticles were diluted 
to 3 mL with water for the size and zeta potential measurement as mentioned earlier. 
Opsonized particles were also analyzed with sodium dodecyl sulphate polyacryl amide gel 
electrophoresis (SDS-PAGE). 
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2.3. Surface Functionalization of TCPSi-NH2 and UnTHCPSi NPs 
with Fluorescent Molecules 
2.3.1. Standard Calibration Curve with FITC and FluorA 
 
Fluorescence intensity was measured with Fluoroskan Ascent FL (Thermo Lab systems) and 
standard calibration curve was plotted with fluorescence intensity versus concentration of 
FITC and FluorA. 
 
2.3.2. Labeling of TCPSi-NH2 Nanoparticles (NPs) with FITC  
 
FITC labeled NPs were prepared by addition of 0.2 mg  of FITC (10 mg/mL in ethanol)  into 
0.2 mg (126.58 µL) of TCPSi-NH2–nanoparticles (1.58 mg/mL in ethanol) in a Eppendorf 
tube and sonicated for about 3 hours in the dark followed by mixing with end-over-end mixer 
overnight at 37
o
C in Termaks incubator. The resulting FITC labeled TCPSiNPs were washed 
by six cycles of centrifugation (20 min).  NPs were washed three times with 1mL ethanol and 
three times with 1mL 50mM HEPES (pH 7.2) to remove unreacted FITC. An ultrasonic bath 
(Branson 2510 E-MT, Danbury, CT, USA) was used to re-suspend the FITC labeled TCPSi-
NH2 NPs in solution after each centrifugation. Finally they were suspended in 200 μL of 50 
mM HEPES (pH 7.2) and stored at +4
0
C. 
 
2.3.2.1. Absorption of Stearylated NickFect 51 (NF51) Cell 
Penetrating Peptides (CPPs) onto the Surface of FITC Labeled 
TCPSi-NH2NPs 
 
 Prior to CPP absorption, 180μL (180μg) of FITC labeled NPs were centrifuged for 20 min at 
13200 rpm and the supernatant was discarded. FITC labeled TCPSi-NH2NPs were washed 
two times with cell culture medium (FCS, PSG). An ultrasonic bath was used to resuspend 
the FITC-TCPSi-NH2 in solution after each centrifugation. Then 18 µL (5.7 mg/mL) of CPPs 
were added into sample. After adding CPPs, the solution was sonicated for 3 hours followed 
by centrifugation and discarding of supernatant. The particles were washed thrice with 
HEPES and resuspended into 180 µL of HEPES. Fluorescence intensity was measured in a 
similar way as mentioned earlier by taking 20 µL (1µg/µL) of sample. 
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2.3.2.2. Conjugation of Radioactive Iodine Labeled Stearylated 
NickFect 51 (NF51) Cell Penetrating Peptides (125I-CPPs) to the 
Surface of FITC Labeled TCPSi-NH2NPs  
 
Prior to 
125
I-CPPs absorption, 130 μL (1µg/µL) of FITC labeled TCPSi-NH2NPs were 
centrifuged for 20 min at 13200 rpm and the supernatant was discarded. FITC labeled TCPSi-
NH2NPs were washed two times with 500 µL of cell culture medium. An ultrasonic bath was 
used to resuspend the FITC labeled TCPSi-NH2 in solution after each centrifugation. Then 
13µL (5.7 mg/mL) of 
125
I-CPPs (9KBq) were added into sample. After adding 
125
I-CPPs, the 
solution was mixed with end-over-end mixture overnight at room temperature. Then the 
mixture was centrifuged and the supernatant was discarded. The particles were washed thrice 
with 500 µL of 10mM HEPES (pH 7.4) and finally modified particles were resuspended into 
500 µL of 10mM HEPES. All of the supernatants were collected into a gamma-counter tube.  
The radioactivity of 
125
I-CPPs conjugated particles was measured with Gammacounter (LKB-
Wallac, Clingamma 1272, Turku, Finland).  
 
2.3.3. Labeling of UnTHCPSiNPs with Fluoresceinamine Isomer-1 
(FluorA) 
 
The carboxyl group of 0.2mg of UnTHCPSiNPs (7.2 mg/mL in ethanol) was activated by 
adding 40mM of DIC (50µL) and NHS (46µL) in ethanol at room temperature to give an N-
hydroxysuccinimide ester -terminated intermediate. 40µmol (13.88mg) of FluorA in ethanol 
was added on NPs, and the mixture was protected from light by wrapping with tinfoil. By 
using end over end mixer (BIOSAN Bio Rotator RS-Multi) NPs were mixed overnight at 
37
o
C in Termaks incubator followed by centrifuging for 20 min and discarding the 
supernatant. The resulting PEGylated TCPSiNPs were separated by six cycles of 
centrifugation (20 min) and washing. PEGylated TCPSiNPs were washed three times with 
1mL of ethanol and then three times with 1mL of 50 mM HEPES (pH 7.2) to remove 
unreacted FluorA.  An ultrasonic bath was used to resuspend the UnTHCPSi-FluorA in 
solution after each centrifugation. Finally labeled NPs were suspended into 200 μL of 50 mM 
HEPES (pH 7.2) and fluorescence intensity was measured in a similar manner as mentioned 
earlier. 
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2.4. Characterization Methods 
2.4.1. Dynamic Light Scattering (DLS) 
 
Size and zeta potential was measured at room temperature (23
0
C) with "Zetasizer Nano-ZS 
by Malvern Instruments", USA by taking 50 µg of PEGylated-TCPSi-NH2NPs which was 
diluted to 3mL with water. Before measuring the particles were sonicated for a while. 
 
2.4.2. Gel Electrophoresis 
 
SDS-PAGE was used for separation of nanoparticles and proteins based on their size. Nine 
samples containing 50µg opsonized NPs, human plasma (1:200) and molecular weight size 
markers were loaded into adjacent wells in the gel. In the gel electophoresis part, the samples 
were suspended into 15µL buffer containing 125mM Tris-HCl (pH 6.8), 2% SDS, 5% 
glycerol, and 0.002% bromophenol blue and were heated about 5 minutes at 100
o
C in block 
heater before loading to the wells. The running buffer was: 1 x SDS electrophoresis buffer 
containing 25 mM Tris-HCl, 200 mM Glycine and 0.1 % Sodium dodecyl sulfate. 10% gel 
with 4% stacking gel was used to run in 100 V, 400mA and approximately 100 minutes. 
Every lane showed separation of the plasma proteins from the original mixture. After running 
the gel was stained with 0.025% Coomassie Brilliant Blue overnight. Finally they were 
washed with water and molecular sizes of the stained proteins were compared to the 
molecular weight standards. 
 
2.4.3. Fluorescence Intensity Measurement 
 
20 μL (1μg/μL) of suspended nanoparticle solution was pipetted into a well (96 plate well) 
and diluted with 180 μL of PBS for the fluorescence measurement. The concentration of the 
particles in the first well was 0.1μg/μL in Phosphate buffer saline (PBS). 100 μL of FITC-
TCPSi-NH2 NPs were titrated serially 1:2 with PBS into next four wells. Fluorescence was 
measured using excitation wave length of 488 nm and emission wave length of 520 with 
Fluoroskan Ascent FL (Thermo Lab systems).  
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3. Results and discussion 
 
To functionalize the surface of the porous silicon nanoparticles with FITC and MeO-PEG-
COOH, we have employed amino thermally carbonized porous silicon nanoparticles (TCPSi-
NH2). Fluoresceinamine isomer-1 (FluorA) has been used for the modification of undecylenic 
acid dervatized thermally hydrocarbonized porous silicon nanaoparticles (UnTHCPSi).  
 
3.1. Surface Modification of TCPSi-NH2 with MeO-PEG-COOH (5.768 
kDa) 
 
Polyethylene glycol conjugation to amino derivated silicon nanoparticles (amide bond) was 
 
Figure 3.1: Formation of amide through the reaction of terminal –NH2 groups in TCPSi-NH2 with –COOH 
groups in MeO-PEG-COOH. 
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achieved via the formation of N-hydroxysuccinimide ester or HBTU as a leaving group 
(reaction scheme shown with DIC/NHS Figure 3.1). 
 
Prior to any modification of the surface, amino groups are responsible for the positive zeta 
potential of the core particle. The size of the original nanoparticles was 170 nm and the zeta 
potential was +70 mV. When using DIC/NHS as activators, the zeta potential shifted to lower 
values (mostly negative zeta potential). Although the zeta-potential and the size changed 
during the conjugation, there was no direct correlation between size, zeta potential and the 
concentrations (Table 3.1.) .The samples containing 20 and 40 mM of DIC and NHS is 
suggested to be aggregated. In conclusion, the changes in size and zeta potential of the 
particles suggest that the surface conjugation of MeO-PEG-COOH to the TCPSi-NH2 NPs 
were successful. 
Table 3.1: Size and zeta potential values of PEGylated TCPSi-NH2 nanoparticles by using MeO-PEG-COOH as 
a surface modifier with different concentration of DIC and NHS as an activator. 
Sample Name Size (nm) Zeta potential (mV) 
Original (plain)  NPs 170 +70 
NP+5mM of DIC and NHS  196 -28.7 
NP+10mM of DIC and NHS  183 +16.3 
NP+20mM of DIC and NHS  922 -1.85 
NP+40mM of DIC and NHS  666 -16.5 
NP+60mM of DIC and NHS  181 -25.2 
NP+80mM of DIC and NHS  171.6 -30.8 
NP+100mM of  DIC and NHS  176.1 -27 
NP+120mM of  DIC and NHS  219 -22.3 
The coupling efficiency was further tested using HBTU as a coupling reagent. The size and 
the zeta-potential of the PEGylated nanoparticles by using HBTU and DIPEA had 
insignificant changes (table 3.2) suggesting insufficient conjugation of PEG.  
Thirdly PEG was also conjugated to the nanoparticles by refluxing. The zeta potential and 
size of refluxed nanoparticles showed significant change indicating successful conjugation 
(Table 3.2, last row). 
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Table 3.2: Size and zeta potential of PEGylated TCPSi-NH2 nanoparticles by using MeO-PEG-COOH as a 
surface modifier and different concentration of HBTU and DIPEA as an activator except last row. 
Sample  Size (nm) Zeta potential (mV) 
NP+ 10mM of HBTU and DIPEA 188 +52 
NP+ 40mM of HBTU and DIPEA 185.7 +53.2 
NP+80mM of HBTU and DIPEA 170.1 +49.4 
NP+120mM of HBTU and DIPEA 196 +54.6 
NP+ 160mM of HBTU and DIPEA 181 +48.3 
NP+200mM of HBTU and DIPEA 194 +51.4 
NP+ MeO-PEG-COOH (reflux) 240 -30.0 
 
3.2. Opsonization of the PEGylated TCPSi-NH2 NPs 
 
Polyethyleneglycol is a relatively inert hydrophilic polymer that provides good steric 
hindrance for preventing protein binding. Comparing the obtained size and zeta potential 
after the opsonization of the PEGylated and original TCPSi-NH2 nanoparticles, lower protein 
adsorption was observed for the PEGylated than for the non-PEGylated particles (Table 3.3).  
Table 3.3: Size and zeta potential values of the investigated opsoninated NPs prepared with DIC and NHS 
Sample   Size(nm) Zeta-potential(mV) 
Plain NPs 357 -31.3 
NP+5mM of DIC and NHS  428 -19 
NP+10mM of DIC and NHS  868 -27.2 
NP+20mM of DIC and NHS  445 -29.1 
NP+40mM of DIC and NHS  358 -31.2 
NP+60mM of DIC and NHS  774 -16.9 
NP+80mM of DIC and NHS  344 -32.7 
NP+100mM of  DIC and NHS  377 -27.8 
NP+120mM of  DIC and NHS  338 -21.5 
  
The zeta potential of the non-PEGylated particles as well as PEGylated particles with positive 
zeta potential was changed to the negative values after opsonization. Nanoparticles 
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conjugated with 120 µmol of DIC and NHS showed the lowest value in the size and zeta 
potential after opsonization suggesting the optimal shielding properties.  
 
 
Figure 3.2: The SDS-PAGE analysis of original and PEGylated nanoparticles:  MW = molecular marker, NP= 
only nanoparticles, R= refluxed sample, 05=5mM of DIC and NHS+ NP + m -PEG-COOH, 10=10mM  of DIC 
and NHS +NP + m-PEG-COOH, 15=15mM of DIC and NHS +NP + m-PEG-COOH, 20=20 mM of DIC and 
NHS +NP + m-PEG-COOH, 40=40 mM of DIC and NHS+ NP + m-PEG-COOH, 60= 60mM of DIC and NHS 
+ NP + m-PEG-COOH, 80=80 mM  of DIC and NHS+NP+m-PEG-COOH,100=100 mM of DIC and 
NHS+NP+m-PEG-COOH,120=120 mM  of DIC and NHS +NP + m-PEG-COOH,       Plasma= human plasma. 
 
The molecular weight and relative adsorption rates of the human plasma proteins were 
analyzed with PAGE (Figure 3.2).  In gel-1, wells containing (40 mM of DIC, NHS, and 60 
mM of DIC, NHS) showed the lower adsorption rate opsonization than other wells. In gel-2, 
well containing (120 mM of DIC and NHS) showed the less opsonization. From gel-3, we 
cannot find significant difference like gel-1 and gel-2. If we compare the gel-1 and gel-2, we 
can conclude that well containing 40 mM of DIC, NHS, and 60 mM of DIC, NHS slightly 
better than the well containing 120 mM of of DIC, NHS of gel-2.  Using relative high 
concentration i.e. 40 - 120 mM of of DIC and NHS, the lowest opsonization degree was 
achieved suggesting the maximal coverage of the nanoparticles with PEG-molecules. From 
the aforementioned discussion we can conclude that the concentration of NHS and DIC 
influenced the activation and the optimum result was found with 40 and 60 mM of DIC and 
NHS. From this point of view, 40 mM concentration of DIC and NHS were used for the 
further PEGylation. The proteins which were adsorbed to the surface of TCPSi-NH2 NPs 
during opsonization may be fibrinogen, Immunoglobulin G (IgG), and Human serum albumin 
(HSA). 
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3.3. Surface Functionalization of TCPSi-NH2 by Using Different Size 
of MeO-PEG-COOH  
 
Surface functionalization of TCPSi-NH2 with different sizes of MeO-PEG-COOH was 
investigated by measuring size and zeta potential. The pegylated-TCPSi-NH2NPS with 
different size of PEG molecules were prepared several times but surprisingly the consistent 
results (size and zeta potential) were not found. We got different results every time. Two of 
test series are shown in the table 3.4(a) and 3.4(b). 
 
Table 3.4a: Zeta potential values of the investigated PEG-TCPSi-NH2 NPs 
Sample  Size(nm) Zeta potential (mV) 
PEG 5.768kDa 210 -16.3 
PEG 11kDa 243 -13.4 
PEG 25kDa 245 -7.8 
 
Table 3.4b: Zeta potential values of the investigated PEG-TCPSi-NH2 NPs 
Sample  Size(nm) Zeta potential (mV) 
PEG 5.768kDa 166.2 -34.3 
PEG 11kDa 176.1 -14.0 
PEG 25kDa 187 -20.1 
 
 Three PEG molecules with different molecular weights were 5.768, 11 and 25kDa. No direct 
correlation was also observed between the molecular weight of the PEG molecule and the 
zeta potential values (Table 3.4b), though all PEG molecules bound to 3-(2-
Aminoethylamino)propyldimethoxymethylsilane (AEASP) amine groups resulting diminish 
of the positive charges introduced and thus causing a negative zeta potential, which could be 
partially interpreted by the charge-shielding effect of PEG backbones. A significant 
correlation was observed between the molecular weight of the PEG molecule and the size 
values. Size was increased with increasing the length of the PEG molecule. 
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3.4. Surface Modification of Amino Thermally Carbonized Porous 
Silicon (TCPSi-NH2) Nanoparticles (NPs) with Fluorescein-5-
isothiocyanate (FITC) 
 
FITC is an organic fluorophore with mainly hydrophobic behavior which is a popular amine 
labeling reagent, forming a thiourea bond upon reaction. The particles are conjugated with 
FITC by a covalent attachment of the dye with an appropriate functional group. Using FITC 
the fluorochrome was covalently bound to AEASP through the isothiocyanate group in the 
dye and the primary amino group of the TCPSi-NH2 (Figure 3.3).  
 
                                  
 
Figure 3.3: Represents covalent conjugation of isothiocyanate with a primary amine. 
 
 
Mechanism of the reaction:  
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The lone pair of nitrogen in primary amine attacks on the carbon of the isothiocyanate group 
resulting negative charge on nitrogen of isothiocyanate group and positive charge on nitrogen 
of primary amine. Finally negatively charged nitrogen abstracts a proton from the positively 
charged nitrogen and consequently thiourea bond is formed.  
 
The fluorescence intensity of FITC-labeled silicon NPs were determined in standard PBS 
solutions (excitation wave length at 488 nm, emission wavelength of 520 nm). The maximum 
emission for FITC-labeled particles is at ~520 nm. The fluorescence intensity of FITC-
labeled NPs is extremely dependent on pH of the solution, screening enhanced intensity in 
basic conditions 
 
In addition, non-covalent conjugation of FITC to the surface may be observed. Non-covalent 
adsorption of FITC varied. Centrifugation and washing cycles totally removed adsorbed 
fluorophores which was confirmed by fluorescence spectroscopy. The surface of covalently 
conjugated SiNPs was considered free of adsorbed labels because they did not fade during 
washing. 
 
The fluorescence intensity of FITC-labeled silicon NPs were determined in standard PBS 
solutions (excitation wave length at 488 nm, emission wavelength of 520 nm). The maximum 
emission for FITC-labeled particles is at ~520 nm. The fluorescence intensity of FITC-
labeled NPs is extremely dependent on pH of the solution, screening enhanced intensity in 
basic conditions.  
 
The determination of a number of FITC conjugated inside the NPs is challenging due to the 
potential effect of self-quenching of dye molecules in close proximity; Calibration curves 
with the pure fluorophore were performed in order to elucidate the number of FITC 
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molecules trapped inside the matrix (Figure 3.4) Linearly dependent fluorescence intensity on 
FITC concentration was observed with regression coefficient 0.995. 
 
 
Figure 3.4: Fluorescence intensity vs. FITC concentration 
 
 
 
Figure 3.5: Fluorescence intensity vs. FITC labeled TCPSi-NH2NPs concentration 
 
 
Linearly dependent fluorescence intensity on FITC labeled NPs concentration was also 
observed (Figure 3.5) with regression coefficient 0.9943. 
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The fluorescence intensity of FITC labeled TCPSi-NH2NPs (10µg/10µL) was 14.7 mV. In 
comparison to the calibration curve, 42.55 nmol of FITC was conjugated to the amino-
modified NPs. The obtained fluorescence intensity of the particles reveals that the surface 
conjugation of FITC to the TCPSi-NH2 NPs were successful. 
After consecutive washing of FITC labeled TCPSi-NH2NPS with both ethanol and HEPES, 
the fluorescence of the supernatant was measured (data not showed) but surprisingly 
fluorescence of the supernatant was higher than the precipitate. NPs interacted with 
fluorescence material and lowered their intensity and this may be a reason for lower 
fluorescence intensity in suspension compared to supernatant as in supernatant there are no 
NPs and for that such interaction is not expected there.  
Dynamic light scattering (Zetasizer) was used to investigate the size and zeta potential of the 
FITC conjugated nanoparticles. Observed single peak reveals uniform size distribution and 
monodispersity of the particles. The size of the Plain TCPSi-NH2 NPs was 170. Significant 
change in particle size was not shown with a mean diameter around (176 nm) in deionized 
water at ambient temperature after fluorescence labeling. The zeta potential of the plain 
TCPSi-NH2 was +70 mV due to the presence of amino groups but after modification with 
FITC, the potential drops to -26 mV which indicates conjugation of FITC to surface. Plain 
NPs have some silanol groups which were remained after FITC labeling and higher negative 
charged was observed on account of silanol groups that were dissociated or deprotonated in 
de-ionized water or oxidation of silanol groups. 
 
3.4.1. Characterization of Stearylated Stearylated NickFect 51 
(NF51) CPPs Adsorped FITC Labeled TCPSi-NH2NPs 
 
Stearylated NickFect 51 (NF51) CPPs conjugated FITC labeled NPs were investigated by 
measuring fluorescence intensity with florescence spectroscopy. Fluorescence intensity (~30) 
of CPPs conjugated FITC labeled NPs were higher than Fluorescence intensity (~14 mV) of 
the FITC labeled NPs which suggests the conjugation of CPPs to the FITC labeled NPs were 
flourishing. It is not conclusive. So for further confirmation radioactive iodine labeled CPPs 
(
125
I-CPPs) were used for the conjugation onto the surface. 
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3.4.2. Characterization of Radioactive Iodine Labeled Stearylated 
NickFect 51 (NF51) Cell Penetrating Peptides Conjugated FITC 
Labeled TCPSi-NH2 NPs 
  
The detection of radioactive materials after the radiolabeling was counted for 1 min by a γ-
counter. The radioactivity was 88%. It reveals that 88% of the added peptide was adsorped to 
NPs surface.  
 
3.5. Surface Modification of UnTHCPSi Nanoparticles (NPs) with 
FluorA 
 
FluorA is an organic dye containing primary amine group which is used to carboxyl acid 
labeling reagent, forming an amide bond during reaction. Fluoresceinamine isomer-
1(FluorA), an amino derivative of fluorescein, was covalently conjugated to the carboxylic 
acid group of the UnTHCPSiNPs with NHS and DIC by mixing overnight at 37
0
C in EtOH 
through reaction route in Figure 3.6. 
 
 
Figure 3.6: Coupling of a carboxylic acid and a primary amine via O-acylisourea ester and NHS ester 
intermediates. 
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As mentioned in figure 3.6, the carbodiimide-mediated conjugation of a carboxylic acid (1) 
with a primary amine first proceed through an unstable intermediate, an O-acylisourea ester 
(3)  produced by the reaction of the carbodiimide (2) with the carboxylic acid (1). Since this 
intermediate is unstable, it is often the case that NHS (N-hydroxysuccinimide) (4) is added to 
the carboxylic acid together with the carbodiimide, in order to form an NHS-ester (5), which 
is a much more stable that remains reactive with amines. Upon the final addition of an amine 
(6), the preferred coupling product, an amide (7), is formed by displacement of the NHS. 
 Thus, in this case, the FluorA was covalently bound to UnTHCPSiNPs through the amine 
group in the dye and the carboxyl acid group of UnTHCPSiNPs. The conjugation of FluorA 
to the UnTHCPSiNPs was investigated by measuring fluorescence intensity. 
 The fluorescence of the FluorA labeled UnTHCPSiNPs was monitored by comparing the 
fluorescence signal of the NPs solution with a calibration curve of the pure dye under the 
same conditions. Though it is not possible to determine the accurate number of dye molecules 
because of the significant effect of self-quenching (proved) of dye molecules in close 
proximity, the determination of the average fluorescence of the NPs is possible. Figure 3.7 
and 3.8 shows a correlation between fluorescence intensity and concentration of the pure dye 
and dye labeled NPs. Linearly dependent fluorescence intensity on FluorA and FluorA 
labeled UnTHCPSiNPs concentration were observed with regression coefficient 0.9933 and 
0.9901. 
 
Figure 3.7: Fluorescence intensity vs. concentration of FluorA. 
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Figure 3.8: Fluorescence intensity vs. concentration of UnTHCPSi-FluorA NPs 
 
The fluorescence intensity of FlourA labeled UnTHCPSiNPS (10µg/10µL) was 2.98 mV. In 
comparison to the calibration curve, 852.43 nmol of FlourA was covalently attached to the 
acid-modified UnTHCPSiNPs. The investigated fluorescence intensity of the particles reveals 
that the surface conjugation of FlourA to the UnTHCPSiNPs was also successful. 
 
Dynamic light scattering (Zetasizer) was used to investigate the size and zeta potential of the 
fluoresceinamine labeled UnTHCPSi nanoparticles. The single peak obtained reveals uniform 
size distribution and monodispersity of the particles. The size of the Plain UnTHCPSiNPs 
was (135-140 nm). The NPs showed a little bit change in particle size with a mean diameter 
around (148 nm) in deionized water at ambient temperature after fluorescence labeling. The 
zeta potential of the plain UnTCPSiNPs was -30 mV due to the presence of carboxyl acid 
groups. Following modification with fluorA, the potential changes to -36 mV.  
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4. Conclusion 
Surface activation of the three different sized (5.768, 11 and 25 kDa) of Me-PEG-COOH was 
carried out by acid termination into succinymidyl (activated) ester by using DIC/NHS action. 
Different concentrations were used to activate the carboxyl acid group (only 5kDa Me-PEG-
COOH) but the concentrations of DIC and NHS must be carefully chosen to ensure optimal 
activation. The activated PEG polymers were conjugated to the amine groups of the amino 
derivatized thermally carbonized porous silicon nanoparticles through the covalent amide 
bond. Aminated thermally carbonized porous silicon nanoparticles were successfully 
functionalized with PEG layer using DIC/NHS as activators but not with HBTU/DIPEA 
reagents. In addition, we tried to PEGylate the nanoparticles by thermal decomposition which 
was also successful. The degree of the conjugation was approximated by size change and zeta 
potential measurements. Potential aggregation was observed in PBS for coated nanoparticles 
after few hours using 20 – 40 mmolar concentrations of DIC/NHS. The efficiency of the 
PEGylated nanoparticle surfaces in preventing biologically nonspecific adsorption of human 
plasma proteins was investigated with opsonization (with 5.768 kDa PEG molecule). High 
degree of PEGylation may change the balance of hydrophilicity and hydrophobicity of the 
nanoparticles. The DIC/NHS activated particles showed lowest opsonization degree 
according to SDS-PAGE analysis. In addition, aggregation caused by 20 - 40 mmolar 
concentration was not observed after opsonization suggesting that plasma proteins or other 
plasma components interrupt the aggregation.  
 
Desirable surface modification of the acid derivated thermally hydrocarbonized porous 
silicon nanoparticles were successfully tailored by flouoresceinamine isomer-1(FluorA) 
through the amide bond formation and the surface of the aminated thermally carbonized 
porous silicon nanoparticles were functionalized with FITC through the thiourea bond 
formation. Compared to the FITC labeled nanoparticles, fluorA labeled nanoparticles were 
screened lower fluorescence intensity because of the self quenching. The stearylated 
NickFect 51 (NF51) CPPs moiety was also successfully adsorbed to FITC labeled TCPSi-
NH2NPs which was screened higher fluorescence intensity and to check the CPPs 
conjugation to the surface of FITC labeled TCPSi-NH2NPs radioactive iodine labeled 
stearylated NickFect 51 cell penetrating peptides was conjugated to FITC labeled TCPSi-NH2 
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NPs which was ensured by Gammacounter. Both fluorescent nanoparticles and stearylated 
NickFect 51 (NF51) cell penetrating peptides conjugated FITC labeled TCPSi-NH2NPs can 
be used as an effective bioimaging probe. 
Complete deployment of PEGylated and fluorescent labeled NPs still hampers due to a 
number of limitations and challenges. Size and specifically zeta potential was not consistent 
for both PEGylated and fluorescent labeled NPs. The higher zeta potential of modified NPs 
was surprising. The minimization of the opsonization was monitored but total minimization 
still to be observed. The fluorescence intensity was higher in the supernatant for fluorescent 
labeled NPs which can be overcome by performing further study. To summarize, our 
experiment turned out successful in minimization of opsonization and obtaining desired 
surface modification of PSiNPs and now next turn is to check out effectiveness these 
modified PSiNPs and continue further research to make those achieved results better. 
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